JP2023552699A5 - - Google Patents
Info
- Publication number
- JP2023552699A5 JP2023552699A5 JP2023528989A JP2023528989A JP2023552699A5 JP 2023552699 A5 JP2023552699 A5 JP 2023552699A5 JP 2023528989 A JP2023528989 A JP 2023528989A JP 2023528989 A JP2023528989 A JP 2023528989A JP 2023552699 A5 JP2023552699 A5 JP 2023552699A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- disease
- compound according
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207969 | 2020-11-17 | ||
| EP20207969.5 | 2020-11-17 | ||
| PCT/EP2021/081678 WO2022106352A1 (en) | 2020-11-17 | 2021-11-15 | New catecholamine prodrugs for use in the treatment of parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552699A JP2023552699A (ja) | 2023-12-19 |
| JP2023552699A5 true JP2023552699A5 (https=) | 2024-11-12 |
Family
ID=73455547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528989A Pending JP2023552699A (ja) | 2020-11-17 | 2021-11-15 | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240025857A1 (https=) |
| EP (1) | EP4247793A1 (https=) |
| JP (1) | JP2023552699A (https=) |
| CN (1) | CN116568672B (https=) |
| WO (1) | WO2022106352A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200225A (es) | 2017-11-24 | 2020-07-25 | H Lundbeck As | Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| EP3972971A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
| WO2020234277A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| JP7641234B2 (ja) | 2019-05-21 | 2025-03-06 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
| WO2020234276A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4543256A (en) | 1982-03-17 | 1985-09-24 | Northeastern University | (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10027887A1 (de) * | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| SE0102036D0 (sv) | 2001-06-08 | 2001-06-08 | Axon Biochemicals Bv | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof |
| US20090124651A1 (en) * | 2007-08-31 | 2009-05-14 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
| TWI404702B (zh) | 2007-08-31 | 2013-08-11 | Lundbeck & Co As H | 兒茶酚胺衍生物和其前藥 |
| TW201036949A (en) | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
| WO2016190871A1 (en) * | 2015-05-28 | 2016-12-01 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-h/halo/ether-phenol compounds |
| MX2019003790A (es) * | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| CR20200225A (es) * | 2017-11-24 | 2020-07-25 | H Lundbeck As | Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson |
| WO2020070099A1 (en) * | 2018-10-02 | 2020-04-09 | H. Lundbeck A/S | Administration of catecholamine prodrugs in combination with a 5-ht2b antagonist |
| JP7641234B2 (ja) | 2019-05-21 | 2025-03-06 | ハー・ルンドベック・アクチエゼルスカベット | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ |
| WO2020234277A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease |
| WO2020234276A1 (en) | 2019-05-21 | 2020-11-26 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| EP3972971A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's diseases |
-
2021
- 2021-11-15 EP EP21807119.9A patent/EP4247793A1/en active Pending
- 2021-11-15 US US18/036,596 patent/US20240025857A1/en active Pending
- 2021-11-15 JP JP2023528989A patent/JP2023552699A/ja active Pending
- 2021-11-15 CN CN202180075492.9A patent/CN116568672B/zh active Active
- 2021-11-15 WO PCT/EP2021/081678 patent/WO2022106352A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552699A5 (https=) | ||
| JP2022533050A5 (https=) | ||
| Kakuta et al. | Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor | |
| JP2017526727A (ja) | インドールアミン−２，３−ジオキシゲナーゼ阻害剤およびその製造方法 | |
| JP2009535340A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP5073708B2 (ja) | 細胞損傷及び炎症疾患の治療または予防用薬学組成物 | |
| US20140303174A1 (en) | Pyridazine derivatives as EAAT2 Activators | |
| BR0011324B1 (pt) | Agonistas de Adrenoceptores Beta 2, Processo de Preparação dos Mesmos, seu Uso e Composição Farmacêutica compreendendo os mesmos | |
| JP2022533912A5 (https=) | ||
| JP2019510039A5 (https=) | ||
| JPH0512329B2 (https=) | ||
| JP2023552699A (ja) | パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ | |
| ES2886571T3 (es) | Inhibidores y sus usos | |
| JP2016534133A (ja) | （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用 | |
| JP2020528913A5 (https=) | ||
| AU2019280031A1 (en) | Histone acetyltransferase activators and uses thereof | |
| JP2024500101A (ja) | 化合物の固体形態 | |
| TW211008B (https=) | ||
| WO2016109359A1 (en) | Cyclopropyl dihydrobenzofuran modulators of melatonin receptors | |
| JOP20240217A1 (ar) | مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة | |
| JP2023157909A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| JP6159388B2 (ja) | タンパク質凝集の阻害剤としてのフェニル−尿素及びフェニル−カルバメート誘導体 | |
| JP2018502092A (ja) | Ｄｒｅａｍ神経カルシウムセンサー−調節化合物、およびその治療的使用 | |
| Krüll et al. | [18F] Fluorine‐Labeled Pharmaceuticals: Direct Aromatic Fluorination Compared to Multi‐Step Strategies |